Evaluation of serum apelin‐13 and apelin‐36 concentrations in preeclamptic pregnancies

摘要

Abstract Aim Recent studies suggest that apelin can be a novel potential therapeutic mediator to improve the diagnosis, and treatment of preeclampsia. This study aimed to investigate the association of serum apelin‐13 and apelin‐36 with preeclampsia and to detect their relationship with preeclampsia‐associated perinatal morbidity. Methods Forty‐four women with preeclampsia were included as the study group. Forty‐four healthy pregnant women, at similar gestational week with similar gravidity, formed the control group. The clinical findings, biochemical indicators, maternal and perinatal outcomes, and the serum concentrations of apelin‐36 and apelin‐13 were evaluated. The levels of apelin‐13 and apelin‐36 were determined with commercial kits using a competition‐based enzyme‐linked immunosorbent assay method. Results The mean gestational age at sampling was 35.77 ±?2.515?weeks in the preeclamptic group, 36.45 ±?2.057?weeks in the control group ( P = 0.270). Maternal serum apelin‐36 and apelin‐13 concentrations were significantly lower in patients with preeclampsia compared to the individuals in the control group ( P = 0.030 and P = 0.005, respectively). The optimal cut‐off points of apelin‐36 and apelin‐13 measurements for discriminating between preeclampsia and controls were evaluated by the receiver–operator curve analysis. The results showed that apelin‐13 and apelin‐36 are moderately successful markers to differentiate subjects with preeclampsia from healthy pregnant women. The concentrations of apelin‐13 and apelin‐36 in both groups were not statistically different in cases with and without adverse fetal/neonatal outcomes. Conclusion In conclusion, we investigated serum apelin‐13 and apelin‐36 concentrations in preeclamptic patients and demonstrated markedly lower maternal concentrations compared to healthy pregnant women.